Oculis SA

Swiss Biotech Association

Member

Oculis S.A. is a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the sight and lives of patients worldwide.

Products, services, technology

OCS-01 being developed in DME and Post-ocular surgery inflammation;
OCS-02 being developed for Uveitis and Dry Eye;
Pre-clinical candidates for retinal disorders and for ocular inflammation

http://www.oculis.com
+41 21 711 39 70
louie-anne.gauthier@oculis.com
Louie-Anne Gauthier

Location

EPFL Innovation Park, 1015 Lausanne, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2017
Number of employees in Switzerland

1-9

Key business

Core competencies

You may also be interested in

PAREXEL International (CH) AG

Parexel is focused on the development of innovative new therapies to improve the world’s health. We do this by providing a suite of groundbreaking biopharmaceutical development services that help customers across the globe transform scientific discoveries into new treatments for patients. From clinical trial design to regulatory and consulting services to commercial and market access, our therapeutic, technical, and functional ability is underpinned by a deep conviction in what we do.
4051 Basel

Perseo pharma AG

Perseo pharma: best-in-class enzyme therapeutics Perseo pharma is a preclinical-stage biotech start-up developing best-in-class enzyme therapeutics based on an innovative proprietary nanotechnology platform.
4057 Basel

Member

Vifor Pharma Management Ltd.

Vifor Pharma Group is a global pharmaceutical company. It aims to become the leader in iron deficiency, nephrology and cardio-renal therapies. The company strives to help patients around the world with severe and chronic diseases lead better, healthier lives.
Glattbrugg

Member